BioIVT is expanding its global commercial capabilities in response to growing demand for its biospecimens and specialized research services
Westbury, NY – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has appointed Alan Findlater to the newly-created role of chief commercial officer. In his new position, Mr. Findlater will be responsible for all of BioIVT’s commercial activities, including global sales, marketing, and customer service.
“Alan is a visionary leader with the requisite knowledge and experience to help guide BioIVT on its rapid growth trajectory as we continue to be the trusted leader for biological products and services,” said BioIVT Chief Executive Officer Jeffrey Gatz.
“Alan has successfully built and led global sales, marketing and commercial operation teams at several major organizations, and his strong services sales background aligns closely with our recent acquisitions. Equally important, he shares BioIVT’s commitment to excellent customer service and product quality. I am delighted to welcome Alan to our executive team.”
“BioIVT is at an exciting inflection point in its development due to a surge in demand for its research models and services. For example, the healthcare industry’s increasing focus on personalized medicine is resulting in a corresponding increase in patient screening and specimen inclusion/exclusion criteria for preclinical development. This is creating a need for more specialized biospecimens, with comprehensive clinical data, to test new drug candidates for safety and efficacy,” said Mr. Findlater.
Mr. Findlater has more than 33 years’ experience in the pharmaceutical, medical device, and R&D services sectors. He was Chief Commercial Officer at WIL Research Laboratories for more than five years before it was acquired by Charles River Laboratories in April 2016.
Mr. Findlater was appointed Charles Rivers’ executive director, global business development, safety assessment, discovery and research models post-acquisition and led the commercial integration of both WIL Research Laboratories and Agilux discovery services.
Prior to that, Mr. Findlater held several senior global management positions at Covance Laboratories Inc., culminating in global vice president of sales and client services Early Pharmaceutical Development.
Mr. Findlater has a bachelor’s degree in chemistry from the University of Strathclyde and a master’s degree in business administration from the University of Warwick Business School, UK.
BioIVT, formerly BioreclamationIVT, is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood, and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.
BioIVT Contact: Courtney Noah, Vice President of Marketing, 516-483-1196
Media Contact: Lisa Osborne, Rana Healthcare Solutions, 206-992-5245, firstname.lastname@example.org